A phase 3 trial of patients with moderate-to-severe TED has shown that subcutaneous injection of Tepezza by way of an on-body ...

The trial met its primary endpoint, demonstrating a statistically significant 77% proptosis response rate at 24 weeks.

Under the agreement, Vertex will make a $15m upfront payment to Halozyme and potential future milestone payments.

Amgen (NASDAQ: AMGN) today announced positive topline results from a Phase 3 trial of TEPEZZA (teprotumumab-trbw) administered by subcutaneous injection via an on-body injector (OBI) in participants ...

Evidence gaps include limited topline safety granularity, unknown long-term follow-up and retreatment rates, and lack of ...

The TEPEZZA OBI trial evaluated the safety and efficacy of SC teprotumumab in patients with active TED and proptosis of 3mm or greater from baseline.

OPDIVO is a prescription medicine used in combination with YERVOY as a first treatment to treat adults with cancer of the ...

Amgen has announced positive topline findings from a phase 3 study evaluating a subcutaneous formulation of Tepezza in adults with moderate to severe active thyroid eye disease (T ...

Learn how subcutaneous nivolumab shifts immunotherapy from IV infusions to quick thigh or abdominal injections, approved in late 2024.

In the new subcutaneous drug delivery landscape, the growing trend towards patient-friendly, at-home administration is ...

As drugmakers strive to fine tune the delivery of their medications for better convenience and patient adherence, Halozyme is putting a recent acquisition in the space to work, thanks to a new tie- | ...

A subcutaneous version of the newly approved Alzheimer's drug lecanemab (Leqembi) may be on the horizon. Weekly subcutaneous lecanemab 100 mg/mL injection appeared to be as effective at amyloid plaque ...